Fortrea reported second-quarter revenue of $678 million, down 4.5% from the prior-year period, while adjusted EBITDA improved nearly 7% to roughly $59 million. Management raised its 2026 revenue and adjusted EBITDA guidance by 212 basis points and 366 basis points, respectively, at the midpoint.
Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies.
Fortrea's margin improvement depends on disciplined cost actions while winning new business, and any operational challenges could delay its recovery.
|
Metric
|
FTRE
|
ICLR
|
MEDP
|
|---|---|---|---|
Price/Earnings (Normalized) | 135.39 | 15.57 | 35.00 |
Price/Book Value | 3.28 | 1.40 | 38.41 |
Price/Sales | 0.63 | 1.58 | 6.19 |
Price/Cash Flow | 32.22 | 13.71 | 27.22 |
|
Metric
|
FTRE
|
ICLR
|
MEDP
|
|---|---|---|---|
Quick Ratio | 0.85 | 0.92 | 0.66 |
Current Ratio | 0.96 | 0.95 | 0.73 |
Interest Coverage | 0.08 | 1.53 | — |
|
Metric
|
FTRE
|
ICLR
|
MEDP
|
|---|---|---|---|
Return on Assets (Normalized) | 2.15% | 3.91% | 26.82% |
Return on Equity (Normalized) | 10.56% | 6.87% | 130.01% |
Return on Invested Capital (Normalized) | 7.32% | 6.21% | 97.04% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|D#lXVD | LOCK|$C&dF | $131B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|FBYcFT | LOCK|xPF@ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|m?RMwX | LOCK|LG | $62B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|T^rBX><c | LOCK|slj?Z | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|j@J%#W | LOCK|d!> | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|f<>#Vy | LOCK|>KSx | $30B | |||
| Moderna Inc
MRNA
| LOCK|fL@QnC& | LOCK|y# | $26B | |||
| Incyte Corp
INCY
| LOCK|j!^Wg!^ | LOCK|jc! | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|!f#F^W | LOCK|FS | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|h%>jk@T | LOCK|Q@b | $16B |
United States